{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:21:47Z","timestamp":1793060507094,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Congenital adrenal hyperplasia (CAH) is a relatively common disorder and one of the most challenging conditions seen by pediatric endocrinologists. Poor linear growth in CAH has been recognized for many years. There are new insights to explain this abnormality and shed light on strategies to promote normal growth.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Published data suggest that the dose of hydrocortisone during two critical periods of rapid growth, namely infancy and at puberty, has a fundamental effect on growth velocity, and by definition adult height. To prevent over-treatment, hydrocortisone dosage should remain within the range of 10\u201315\u200amg\/m<jats:sup>2<\/jats:sup> body surface area per day. Precursor steroids such as 17-hydroxy progesterone (17OHP) should not be suppressed to undetectable levels. In fact, 17OHP should always be measurable, as complete suppression suggests over-treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>CAH is a challenging disorder. High-quality compliance within the consultation setting, with the patient seeing the same specialist at every visit, will be rewarded by improved long-term growth potential. Quality auxological monitoring can avoid phases of growth suppression. New therapy with CRH receptor antagonists may lead to a more nuanced approach by allowing fine tuning of hydrocortisone replacement without the need to suppress ACTH secretion.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001361","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T06:03:32Z","timestamp":1715753012000},"page":"463-466","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Linear growth in children and adolescents with congenital adrenal hyperplasia"],"prefix":"10.1097","volume":"36","author":[{"given":"Martin O.","family":"Savage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia: current insights in pathophysiology diagnostics and management","volume":"43","author":"Claahson-van der Grinten","year":"2022","journal-title":"Endocr Rev"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cen.14131","article-title":"Abnormal liner growth in paediatric adrenal diseases","volume":"92","author":"Minnetti","year":"2020","journal-title":"Clin Endocrinol"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1210\/er.2002-0033","article-title":"Systemic and local regulation of the growth plate","volume":"24","author":"Van der Eerden","year":"2003","journal-title":"Endocr Rev"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2478\/v10042-009-0007-1","article-title":"Morphology and physiology of the epiphyseal growth plate","volume":"47","author":"Burdan","year":"2009","journal-title":"Folia Histochem Cytobiol"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/9467","article-title":"VEGF couples hypertrophic cartilage remodelling, ossification and angiogenesis during endochondral bone formation","volume":"5","author":"Gerber","year":"1999","journal-title":"Nat Med"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/endo.139.7.6099","article-title":"Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH- and IGF-I-receptor in cultured rat chondrocytes","volume":"139","author":"Jux","year":"1998","journal-title":"Endocrinol"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1152\/physrev.00011.2015","article-title":"Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy","volume":"96","author":"Hartmann","year":"2016","journal-title":"Physio Rev"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2164-8-205","article-title":"Expression profiling of Dexamethasone-treated primary chondrocytes identifies targets of glucocorticoid signalling in endochondral bone development","volume":"8","author":"James","year":"2007","journal-title":"BMC Genom"},{"issue":"(Suppl B)","key":"R9-20250730","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1096-6374(98)80024-5","article-title":"Neuroendocrine control of pulsatile growth hormone release in the human: relationship with gender","volume":"8","author":"Veldhuis","year":"1998","journal-title":"Growth Horm IGF Res"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1677\/jme.0.0230209","article-title":"Testosterone effect on growth and growth mediators of the GH-IGF-I axis in the liver and epiphyseal growth plate of juvenile rats","volume":"23","author":"Zung","year":"1999","journal-title":"J Mol Endocrinol"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/archdischild-2016-311910","article-title":"Cardiovascular health, growth and gonadal function in children and adolescents with congenital adrenal hyperplasia","volume":"102","author":"Mooij","year":"2017","journal-title":"Arch Dis Child"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1210\/jc.2009-2616","article-title":"Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis","volume":"95","author":"Muthusamy","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"E1547","DOI":"10.1210\/jc.2014-1486","article-title":"Relationship between final height and health outcomes in adults with congenital adrenal hyperplasia: United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE)","volume":"99","author":"Han","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2009-2631","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline","volume":"95","author":"Speiser","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000316973","article-title":"Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone","volume":"75","author":"Bonfig","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MED.0000000000000308","article-title":"Growth and development in children with classic congenital adrenal hyperplasia","volume":"24","author":"Bonfig","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1365-2265.2002.01645.x","article-title":"Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome","volume":"57","author":"Manoli","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1210\/jc.2009-0942","article-title":"Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation","volume":"94","author":"Bonfig","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jpeds.2014.11.027","article-title":"The relation of peripubertal and pubertal growth to final adult height in children with classic congenital adrenal hyperplasia","volume":"166","author":"Bomberg","year":"2015","journal-title":"J Pediatr"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jpeds.2014.01.011","article-title":"Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-The Minnesota cohort","volume":"164","author":"Sarafoglou","year":"2014","journal-title":"J Pediatr"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.beem.2015.07.004","article-title":"DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease","volume":"29","author":"Suntharalingham","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000337217","article-title":"Absence of clinically relevant growth acceleration in untreated children with nonclassical congenital adrenal hyperplasia","volume":"77","author":"Pijnenburg-Kleizen","year":"2012","journal-title":"Horm Res Paediatr"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/apa.12147","article-title":"Adult height of subjects with nonclassical 21-hydroxylase deficiency","volume":"102","author":"Eyal","year":"2013","journal-title":"Acta Paediatr"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1210\/jc.2019-00031","article-title":"Measurement of salivary adrenal-specific androgens as biomarkers of therapy control in 21-hydroxylase deficiency","volume":"104","author":"Bacila","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/17446651.2018.1455496","article-title":"Immediate-release granule formulation of hydrocortisone, Alkindi\u00ae, for treatment of paediatric adrenal insufficiency (Infacort development programme)","volume":"13","author":"Porter","year":"2018","journal-title":"Expert Rev Endocrinol Metab"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1210\/clinem\/dgad270","article-title":"Crinecerfont, a CRF1 receptor antagonist, lowers adrenal androgens in adolescents with congenital adrenal hyperplasia","volume":"108","author":"Newfield","year":"2023","journal-title":"J Cin Endocrinol Metab"},{"key":"R27-20250730","first-page":"1511","article-title":"Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia","volume":"86","author":"Quintos","year":"2001","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:07:04Z","timestamp":1753898824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001361","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]}}}